Researchers at Baylor College of Medicine and Rice University received a $2.3 million Breakthrough Award from the Department of Defense Congressionally Directed Medical Research Programs to develop a novel NanoGel antibody therapy that targets ER+ breast cancer that has metastasized to bone.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
